WATERTOWN, Mass.--(BUSINESS WIRE)--Captivate Bio, a newly formed scientific solutions provider headquartered in Watertown, Massachusetts, emerged from stealth mode today to announce it has successfully launched its portfolio of cell culture tools to assist in the fight against COVID-19 and other emerging diseases as well as help address the gaps exposed by supply chain issues and delays in cell culture media manufacturing here in the United States.

Captivate Bio initiated operations in June 2020 and has achieved several critical milestones including the first product shipment to customers in just 2 short months while inking key scientific collaborations which will help fuel the Company's aggressive growth strategy. Founded by and women-led, the management team has extensive experience in media manufacturing, supply chain and commercialization; the company is already transacting and rapidly generating revenue.

More on Boston Chron

• State Street Elects Julio Portalatin and John Rhea to Its Board of Directors
• AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• Calvetta Phair, CEO of PEP Travel Group and Waldron McCritty, CEO of BE LUX, Alumni of ASCEND 2020, form teaming alliance to promote Luxury Hospitality
• Ameresco Announces Pricing of Public Offering of Class A Common Stock
• Bank on Boston partnership to support unbanked and underbanked Boston residents

"Our experience in commercialization and media manufacturing coupled with operational excellence has enabled us to reach these milestones fairly quickly; we are focused on the customer first and in helping researchers get access to tools they need at an affordable price," says Chief Executive, Tanya Potcova. The Captivate Bio team's experience in sourcing raw materials, commercialization, and supply chain know-how has allowed them to successfully launch a portfolio of research products efficiently.

The company holds memberships with Mass Bio, BioCT, and plans for operational expansions are currently underway.

"Our team shares a passion for science and the customer. We've set out on this journey to help researchers solve procurement challenges exposed during this global pandemic," says Lori Oakes, Managing Partner of Captivate Bio. "We couldn't be prouder of our small, passionate team that worked tirelessly to get our first products off the shelf. This was truly a team effort."

More on Boston Chron

• Boston: Renovations of historic Roxbury Lenox Apartments begin
• Compass Therapeutics Announces Participation in March 2021 Investor Conferences
• Massachusetts: Baker-Polito Administration Awards Nearly $40 Million in Grants to 1,026 Additional Businesses for COVID Relief
• Adare Biome™ Enters North American Distribution Through Stratum Nutrition® for LBiome™ Postbiotic
• Gillette® Announces the Return of the Gillette Gaming Alliance

ABOUT CAPTIVATE BIO

Captivate Bio is a privately held scientific solutions provider specializing in the commercialization and distribution of high-quality reagents and custom cell culture media services for the research, therapeutic, and healthcare communities. Captivate Bio's current focus is in supplying high volume media and supplements to assist in the fight against COVID-19 and future diseases. Current product offering includes viral transport media and collection kits plus classical cell culture media, fetal bovine serum (FBS), human platelet lysate (HPL), and a portfolio of small molecules for stem cell research. Visit www.captivatebio.com or follow-on LinkedIn, Facebook, Instagram, and Twitter.

---

Show All News | Report Violation